Alendronate Sodium Oral Solution, 70 mg/75 mL recall — Hikma Pharmaceuticals Usa Inc (Class II)

Hikma Pharmaceuticals Usa Inc is recorded by the U.S. Food and Drug Administration (FDA) as recalling Alendronate Sodium Oral Solution, 70 mg/75 mL — a Class II recall, initiated 2026-04-07 and posted to the FDA enforcement report on 2026-05-06, under recall number D-0526-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.”. From the product description, the form is oral solution, the strengths given are 70 mg/75 mL and 75 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 0054-0282-59. Distribution is recorded as “US Nationwide” — Nationwide (US), with the recalling firm on record in OH, United States. It is the only recall number the FDA has filed under event ID 98744. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0526-2026
FDA event ID 98744
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Hikma Pharmaceuticals Usa Inc
Recall initiated 2026-04-07
Reported by FDA 2026-05-06
Report lag 29 days from initiation to report
Distribution US Nationwide. — Nationwide (US)
Firm location on record OH, United States
Product description (source) Alendronate Sodium Oral Solution, 70 mg/75 mL, 75 mL, Rx only, 4 x 75 mL Single Dose Bottles, Distr. by: Hikma Pharmaceuticals USA Inc., Berkeley Heights, NJ 07922, NDC 0054-0282-59.

Reason reported by FDA

This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side.

23 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

5 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.

Product named Alendronate Sodium Oral Solution
Form Oral Solution
Strength 70 mg/75 mL · 75 mL
NDC 0054-0282-59
Marketing category Rx only

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Systane, 10gD-0491-2026Alcon Research LLCClass II2026-05-06
GenTeal Tears, 10gD-0492-2026Alcon Research LLCClass II2026-05-06
Optase Dry Eye Intense Drops (Glycerin 0.2%)D-0499-2026Scope HealthClass II2026-05-06
iVIZIA, 0.5%D-0500-2026Thea Pharma, Inc.Class II2026-05-06
Similasan, 0.5%D-0501-2026Thea Pharma, Inc.Class II2026-05-06
Phenylephrine Hydrochloride Injectable Solution, 40mgD-0502-2026Wells Pharma OF Houston LLCClass II2026-05-06
fentaNYL Citrate Injectable Solution, 1000 mcg/100 mLD-0503-2026Wells Pharma OF Houston LLCClass II2026-05-06
fentaNYL Citrate injectable Solution in 0.9% Sodium ChlorideD-0504-2026Wells Pharma OF Houston LLCClass II2026-05-06

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-05-06 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
fentaNYL Citrate Injectable Solution, 1250 mcg/25mLD-0505-2026Wells Pharma OF Houston LLC1250 mcg/25mL · Solution2026-05-06
fentaNYL Citrate Injectable Solution in 0.9% Sodium ChlorideD-0506-2026Wells Pharma OF Houston LLC0.9% · Solution2026-05-06
Ketamine Hydrochloride Injectable Solution, 50mg/mlD-0507-2026Wells Pharma OF Houston LLC50mg/ml · Solution2026-05-06
fentaNYL Citrate Injectable Solution in 0.9% Sodium ChlorideD-0508-2026Wells Pharma OF Houston LLC0.9% · Solution2026-05-06
Furosemide Tablets, 80 mgD-0486-2026Leading Pharma, LLC80 mg · Tablets2026-04-29
FRESHKOTE LUBRICANT EYEDROPS, 10mLD-0489-2026Harrow Eye LLC10mL2026-04-29
Omega-3-Acid, 1 gramD-0493-2026The Harvard Drug Group LLC1 gram · Capsules2026-04-29
DEXTROSE INJECTION USP, 70%D-0496-2026B Braun Medical Inc70% · Injection2026-04-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 0054-0282-59 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Hikma Pharmaceuticals Usa Inc (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0526-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0526-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-06
Ingested
2026-08-22
Record hash
79ea820dbdf80018

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.